Bryan Yoon
Chief Operating Officer at TERNS PHARMACEUTICALS, INC.
Net worth: 404 371 $ as of 2024-04-29
Bryan Yoon active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Chief Operating Officer | 2020-10-31 | - |
| General Counsel | 2020-10-31 | - | |
| Corporate Secretary | 2020-12-31 | - |
Career history of Bryan Yoon
Former positions of Bryan Yoon
| Companies | Position | Start | End |
|---|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Chief Administrative Officer | 2019-10-31 | 2020-11-05 |
| General Counsel | 2019-10-31 | 2020-11-05 | |
| Corporate Secretary | 2019-10-31 | 2020-11-05 | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 2018-01-07 | 2019-06-06 |
| NIGHTSTAR THERAPEUTICS PLC | General Counsel | 2017-10-31 | 2019-05-31 |
| Corporate Secretary | 2018-01-31 | 2019-05-31 | |
| INTERCEPT PHARMACEUTICALS, INC. | General Counsel | 2012-12-31 | 2017-10-31 |
| Corporate Secretary | 2012-12-31 | 2017-10-31 |
Training of Bryan Yoon
| Cornell University | Graduate Degree |
| The University of Michigan Law School | Graduate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 3 |
Operational
| General Counsel | 4 |
| Corporate Secretary | 4 |
| Graduate Degree | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Bryan Yoon
- Experience
